Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma

Journal of Clinical Investigation

Volumn 122, Issue 11, 2012, Pages 4025-4036

  McKee, Chad M ^a   Xu, Danmei ^a   Cao, Yunhong ^a   Kabraji, Sheheryar ^a   Allen, Danny ^a   Kersemans, Veerle ^a   Beech, John ^a   Smart, Sean ^a   Hamdy, Freddie ^a   Ishkanian, Adrian ^b   Sykes, Jenna ^b   Pintile, Melania ^b   Milosevic, Michael ^b   Van Der Kwast, Theodorus ^b   Zafarana, Gaetano ^b   Ramnarine, Varune Rohan ^b   Jurisica, Igor ^b   Mallof, Chad ^c   Lam, Wan ^c   Bristow, Robert G ^b   Muschel, Ruth J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASE NEXIN I; SONIC HEDGEHOG PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; SERPIN E2; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84868629685     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59348     Document Type: Article

References (63)

1. Jemal A, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. (Pubitemid 351521864)
2. Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer. 2005;104(5):891-905. (Pubitemid 41170215)
3. Lawrentschuk N, Klotz L. Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol. 2011;8(6):312-320.
4. Mottet N, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572-583.
5. Ishkanian AS, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate. 2009;69(10):1091-1100.
6. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
7. Mimeault M, Batra SK. Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med. 2011;17(9-10):949-964.
8. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15(23):3059-3087. (Pubitemid 33115673)
9. Karhadkar SS, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431(7009):707-712. (Pubitemid 39382619)
10. Fan L, et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology. 2004;145(8):3961-3970. (Pubitemid 39037585)
11. Thayer SP, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425(6960):851-856. (Pubitemid 37355945)
12. Berman DM, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425(6960):846-851. (Pubitemid 37351469)
13. Azoulay S, et al. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol. 2008;216(4):460-470.
14. Bigelow RL, et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem. 2004;279(2):1197-1205. (Pubitemid 38082643)
15. Li X, et al. Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene. 2006;25(4):609-621. (Pubitemid 43164471)
16. Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer. 2006;42(4):437-445. (Pubitemid 43227920)
17. Sanchez P, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A. 2004;101(34):12561-12566. (Pubitemid 39122063)
18. Caro I, Low JA. The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res. 2010;16(13):3335-3339.
19. Tang JY, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-2188.
20. Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
21. McMillan R, Matsui W. Molecular pathways: The Hedgehog signaling pathway in cancer. Clin Cancer Res. 2012;18(18):4883-4888.
22. Baker JB, Low DA, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell. 1980;21(1):37-45. (Pubitemid 10040053)
23. Stone SR, Nick H, Hofsteenge J, Monard D. Glial-derived neurite-promoting factor is a slow-binding inhibitor of trypsin, thrombin, and urokinase. Arch Biochem Biophys. 1987;252(1):237-244. (Pubitemid 17006015)
24. Donovan FM, Vaughan PJ, Cunningham DD. Regulation of protease nexin-1 target protease specificity by collagen type IV. J Biol Chem. 1994;269(25):17199-17205. (Pubitemid 24204043)
25. Cunningham DD, Van Nostrand WE, Farrell DH, Campbell CH. Interactions of serine proteases with cultured fibroblasts. J Cell Biochem. 1986;32(4):281-291. (Pubitemid 17218674)
26. Bouton MC, Venisse L, Richard B, Pouzet C, Arocas V, Jandrot-Perrus M. Protease nexin-1 interacts with thrombomodulin and modulates its anticoagulant effect. Circ Res. 2007;100(8):1174-1181. (Pubitemid 46684130)
27. Wagner SL, et al. Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(21):8284-8288. (Pubitemid 19286044)
28. Buchholz M, et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 2003;63(16):4945-4951. (Pubitemid 37022630)
29. Fayard B, et al. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res. 2009;69(14):5690-5698.
30. Nagahara A, et al. SERPINE2 is a possible candidate promotor for lymph node metastasis in testicular cancer. Biochem Biophys Res Commun. 2010;391(4):1641-1646.
31. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174. (Pubitemid 37328786)
32. Xu D, Suenaga N, Edelmann MJ, Fridman R, Muschel RJ, Kessler BM. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics. 2008;7(11):2215-2228.
33. Shariat SF, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007;25(4):349-355. (Pubitemid 350002982)
34. Xu D, McKee CM, Cao Y, Ding Y, Kessler BM, Muschel RJ. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res. 2010;70(17):6988-6998.
35. Vaillant C, et al. Protease nexin 1 and its receptor LRP modulate SHH signalling during cerebellar development. Development. 2007;134(9):1745-1754. (Pubitemid 46796571)
36. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998;280(5369):1603-1607. (Pubitemid 28277705)
37. Taipale J, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406(6799):1005-1009.
38. Knauer MF, Kridel SJ, Hawley SB, Knauer DJ. The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins. J Biol Chem. 1997;272(46):29039-29045. (Pubitemid 27498190)
39. Knauer MF, Hawley SB, Knauer DJ. Identification of a binding site in protease nexin I (PN1) required for the receptor mediated internalization of PN1-thrombin complexes. J Biol Chem. 1997;272(19):12261-12264. (Pubitemid 27203308)
40. Silverman GA, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001;276(36):33293-33296.
41. Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002;102(12):4751-4804.
42. Crisp RJ, Knauer DJ, Knauer MF. Roles of the heparin and low density lipid receptor-related proteinbinding sites of protease nexin 1 (PN1) in urokinase-PN1 complex catabolism. J Biol Chem. 2000;275(26):19628-19637.
43. Czekay RP, Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol. 2009;220(3):655-663.
44. Wong H, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res. 2011;17(14):4682-4692.
45. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57(16):3325-3330. (Pubitemid 27355467)
46. Ishkanian AS, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol. 2010;49(7):888-894.
47. Kim TJ, Lee JY, Hwang TK, Kang CS, Choi YJ. Hedgehog signaling protein expression and its association with prognostic parameters in prostate cancer: a retrospective study from the view point of new 2010 anatomic stage/prognostic groups. J Surg Oncol. 2011;104(5):472-479.
48. Yoshizaki A, Nakayama T, Naito S, Wen CY, Sekine I. Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis. World J Gastroenterol. 2006;12(35):5687-5691. (Pubitemid 44594045)
49. Kubo M, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 2004;64(17):6071-6074. (Pubitemid 39129406)
50. Von Hoff DD, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
51. Bumcrot DA, Takada R, McMahon AP. Proteolytic processing yields two secreted forms of sonic hedgehog. Mol Cell Biol. 1995;15(4):2294-2303.
52. Stecca B, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A. 2007;104(14):5895-5900. (Pubitemid 47175630)
53. Tian H, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A. 2009;106(11):4254-4259.
54. Yauch RL, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455(7211):406-410.
55. Pola R, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med. 2001;7(6):706-711. (Pubitemid 32588027)
56. Nakamura K, et al. Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS One. 2010;5(1):e8824.
57. Olive KP, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
58. Lee MJ, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A. 2012;109(20):7859-7864.
59. Van Baelen A, Mottet N, Spahn M, Briganti A, Gontero P, Joniau S. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. Adv Urol. 2012;2012:983058.
60. Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-1947. (Pubitemid 27148818)
61. Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648. (Pubitemid 41528150)
62. Clark J, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26(18):2667-2673. (Pubitemid 46632014)
63. Kasperczyk H, Baumann B, Debatin KM, Fulda S. Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. FASEB J. 2009;23(1):21-33.